首页> 外文期刊>Oncogenesis. >Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy
【24h】

Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy

机译:针对癌症干细胞的自我更新途径:对癌症治疗的临床意义

获取原文
           

摘要

Extensive cancer research in the past few decades has identified the existence of a rare subpopulation of stem cells in the grove of cancer cells. These cells are known as the cancer stem cells marked by the presence of surface biomarkers, multi-drug resistance pumps and deregulated self-renewal pathways (SRPs). They have a crucial role in provoking cancer cells leading to tumorigenesis and its progressive metastasis. Cancer stem cells (CSCs) are much alike to normal stem cells in their self-renewal mechanisms. However, deregulations in the SRPs are seen in CSCs, making them resistant to conventional chemotherapeutic agents resulting in the tumor recurrence. Current treatment strategies in cancer fail to detect and differentiate the CSCs from their non-tumorigenic progenies owing to absence of specific biomarkers. Now, it has become imperative to understand complex functional biology of CSCs, especially the signaling pathways to design improved treatment strategies to target them. It is hopeful that the SRPs in CSCs offer a promising target to alter their survival strategies and impede their tumorigenic potential. However, there are many perils associated with the direct targeting method by conventional therapeutic agents such as off targets, poor bioavailability and poor cellular distribution. Recent evidences have shown an increased use of small molecule antagonists directly to target these SRPs may lead to severe side-effects. An alternative to solve these issues could be an appropriate nanoformulation. Nanoformulations of these molecules could provide an added advantage for the selective targeting of the pathways especially Hedgehog, Wnt, Notch and B-cell-specific moloney murine leukemia virus integration site 1 in the CSCs while sparing the normal stem cells. Hence, to achieve this goal a complete understanding of the molecular pathways corroborate with the use of holistic nanosystem (nanomaterial inhibition molecule) could possibly be an encouraging direction for future cancer therapy.
机译:在过去的几十年中,广泛的癌症研究已经确定了在癌细胞丛中存在着稀有的干细胞亚群。这些细胞被称为癌症干细胞,其特征是存在表面生物标记物,多药耐药泵和失控的自我更新途径(SRP)。它们在激发导致肿瘤发生及其进行性转移的癌细胞中起着至关重要的作用。癌症干细胞(CSC)的自我更新机制与正常干细胞非常相似。但是,在CSC中发现SRP的失调,使其对常规化疗药物具有抗性,导致肿瘤复发。由于缺乏特异性生物标志物,目前的癌症治疗策略无法将CSC与非肿瘤发生子代相鉴别。现在,必须了解CSC的复杂功能生物学,尤其是设计针对它们的改良治疗策略的信号通路。希望CSC中的SRP提供一个有前途的目标,以改变其生存策略并阻止其致瘤潜力。然而,通过常规治疗剂的直接靶向方法存在许多危险,例如脱靶,不良的生物利用度和不良的细胞分布。最近的证据表明,直接使用小分子拮抗剂直接靶向这些SRP可能会导致严重的副作用。解决这些问题的替代方法可以是适当的纳米制剂。这些分子的纳米制剂可以为CSCs中的途径特别是Hedgehog,Wnt,Notch和B细胞特异性莫洛尼鼠白血病病毒整合位点1的选择性靶向提供额外的优势,同时又保留了正常的干细胞。因此,为了实现该目标,对与整体纳米系统(纳米材料抑制分子)的使用相关的分子途径的完整理解可能是未来癌症治疗的令人鼓舞的方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号